Early and late onset Alzheimer's disease patients have distinct patterns of white matter damage

Neurobiology of Aging

Volumn 33, Issue 6, 2012, Pages 1023-1033

  Canu, Elisa ^a   Frisoni, Giovanni B ^b   Agosta, Federica ^a   Pievani, Michela ^a,b   Bonetti, Matteo ^c   Filippi, Massimo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c Neuroradiology Service   (Italy)

Author keywords

Alzheimer's disease; Atrophy; Early onset; VBM; White matter

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

AGED; ALZHEIMER DISEASE; ANATOMICAL VARIATION; ARTICLE; BRAIN ATROPHY; BRAIN DAMAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; GRAY MATTER; HUMAN; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PRIORITY JOURNAL; VOXEL BASED MORPHOMETRY; WHITE MATTER;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE FIBERS, MYELINATED; NEUROPSYCHOLOGICAL TESTS;

EID: 84859483717     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.09.021     Document Type: Article

References (64)

1. Agosta F., Vossel K.A., Miller B.L., Migliaccio R., Bonasera S.J., Filippi M., Boxer A.L., Karydas A., Possin K.L., Gorno-Tempini M.L. Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2018-2022.
2. Amodio P., Wenin H., Del Piccolo F., Mapelli D., Montagnese S., Pellegrini A., Musto C., Gatta A., Umilta C. Variability of trail making test, symbol digit test and line trait test in normal people. A normative study taking into account age-dependent decline and sociobiological variables. Aging Clin. Exp. Res 2002, 14:117-131.
3. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007, 38:95-113.
4. Ashburner J., Friston K.J. Unified segmentation. Neuroimage 2005, 26:839-851.
5. Bartzokis G., Lu P.H., Geschwind D.H., Tingus K., Huang D., Mendez M.F., Edwards N., Mintz J. Apolipoprotein E affects both myelin breakdown and cognition: implications for age-related trajectories of decline into dementia. Biol. Psychiatry 2007, 62:1380-1387.
6. Bozzali M., Falini A., Franceschi M., Cercignani M., Zuffi M., Scotti G., Comi G., Filippi M. White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J. Neurol. Neurosurg. Psychiatry 2002, 72:742-746.
7. Bronge L., Bogdanovic N., Wahlund L.O. Postmortem MRI and histopathology of white matter changes in Alzheimer brains. A quantitative, comparative study. Dement. Geriatr. Cogn. Disord 2002, 13:205-212.
8. Bronge L., Fernaeus S.E., Blomberg M., Ingelson M., Lannfelt L., Isberg B., Wahlund L.O. White matter lesions in Alzheimer patients are influenced by apolipoprotein E genotype. Dement. Geriatr. Cogn. Disord 1999, 10:89-96.
9. Caffarra P., Vezzadini G., Dieci F., Zonato F., Venneri A. Rey-Osterrieth complex figure: normative values in an Italian population sample. Neurol. Sci 2002, 22:443-447.
10. Canu E., McLaren D.G., Fitzgerald M.E., Bendlin B.B., Zoccatelli G., Alessandrini F., Pizzini F.B., Ricciardi G.K., Beltramello A., Johnson S.C., Frisoni G.B. Microstructural diffusion changes are independent of macrostructural volume loss in moderate to severe Alzheimer's disease. J. Alzheimers Dis 2010, 19:963-976.
11. Carlesimo G.A., Caltagirone C., Gainotti G. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur. Neurol 1996, 36:378-384.
12. Chaim T.M., Duran F.L., Uchida R.R., Perico C.A., de Castro C.C., Busatto G.F. Volumetric reduction of the corpus callosum in Alzheimer's disease in vivo as assessed with voxel-based morphometry. Psychiatry Res. 2007, 154:59-68.
13. Coffey C.E., Wilkinson W.E., Parashos I.A., Soady S.A., Sullivan R.J., Patterson L.J., Figiel G.S., Webb M.C., Spritzer C.E., Djang W.T. Quantitative cerebral anatomy of the aging human brain: a cross-sectional study using magnetic resonance imaging. Neurology 1992, 42:527-536.
14. Cosentino S., Scarmeas N., Helzner E., Glymour M.M., Brandt J., Albert M., Blacker D., Stern Y. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 2008, 70:1842-1849.
15. Double K.L., Halliday G.M., Kril J.J., Harasty J.A., Cullen K., Brooks W.S., Creasey H., Broe G.A. Topography of brain atrophy during normal aging and Alzheimer's disease. Neurobiol. Aging 1996, 17:513-521.
16. Englund E. Neuropathology of white matter changes in Alzheimer's disease and vascular dementia. Dement. Geriatr. Cogn. Disord 1998, 9(suppl 1):6-12.
17. Englund E., Brun A. White matter changes in dementia of Alzheimer's type: the difference in vulnerability between cell compartments. Histopathology 1990, 16:433-439.
18. Englund E., Brun A., Alling C. White matter changes in dementia of Alzheimer's type. Biochemical and neuropathological correlates. Brain 1988, 111:1425-1439.
19. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
20. Fellgiebel A., Muller M.J., Wille P., Dellani P.R., Scheurich A., Schmidt L.G., Stoeter P. Color-coded diffusion-tensor-imaging of posterior cingulate fiber tracts in mild cognitive impairment. Neurobiol. Aging 2005, 26:1193-1198.
21. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res 1975, 12:189-198.
22. Frisoni G.B., Beltramello A., Weiss C., Geroldi C., Bianchetti A., Trabucchi M. Linear measures of atrophy in mild Alzheimer disease. AJNR Am. J. Neuroradiol 1996, 17:913-923.
23. Frisoni G.B., Pievani M., Testa C., Sabattoli F., Bresciani L., Bonetti M., Beltramello A., Hayashi K.M., Toga A.W., Thompson P.M. The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain 2007, 130:720-730.
24. Frisoni G.B., Testa C., Sabattoli F., Beltramello A., Soininen H., Laakso M.P. Structural correlates of early and late onset Alzheimer's disease: voxel based morphometric study. J. Neurol. Neurosurg. Psychiatry 2005, 76:112-114.
25. Geroldi C., Pihlajamaki M., Laakso M.P., DeCarli C., Beltramello A., Bianchetti A., Soininen H., Trabucchi M., Frisoni G.B. APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 1999, 53:1825-1832.
26. Gunning-Dixon F.M., Brickman A.M., Cheng J.C., Alexopoulos G.S. Aging of cerebral white matter: a review of MRI findings. Int. J. Geriatr. Psychiatry 2009, 24:109-117.
27. Hanyu H., Nakano S., Abe S., Arai H., Iwamoto T., Takasaki M. [Differences of neuroimaging between early-onset and late-onset Alzheimer-type dementia]. Rinsho Shinkeigaku 1995, 35:1104-1109.
28. Hashimoto M., Yasuda M., Tanimukai S., Matsui M., Hirono N., Kazui H., Mori E. Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer's disease. Neurology 2001, 57:1461-1466.
29. Head D., Buckner R.L., Shimony J.S., Williams L.E., Akbudak E., Conturo T.E., McAvoy M., Morris J.C., Snyder A.Z. Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging. Cereb. Cortex 2004, 14:410-423.
30. Hirono N., Hashimoto M., Yasuda M., Ishii K., Sakamoto S., Kazui H., Mori E. The effect of APOE epsilon4 allele on cerebral glucose metabolism in AD is a function of age at onset. Neurology 2002, 58:743-750.
31. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res 1990, 31:545-548.
32. Honea R.A., Vidoni E., Harsha A., Burns J.M. Impact of APOE on the Healthy Aging Brain: A Voxel-Based MRI and DTI Study. J. Alzheimers Dis 2009, 18:553-564.
33. Hughes C.P., Berg L., Danziger W.L., Coben L.A., Martin R.L. A new clinical scale for the staging of dementia. Br. J. Psychiatry 1982, 140:566-572.
34. Ichimiya A., Herholz K., Mielke R., Kessler J., Slansky I., Heiss W.D. Difference of regional cerebral metabolic pattern between presenile and senile dementia of the Alzheimer type: a factor analytic study. J. Neurol. Sci 1994, 123:11-17.
35. Ishii K., Kawachi T., Sasaki H., Kono A.K., Fukuda T., Kojima Y., Mori E. Voxel-based morphometric comparison between early- and late-onset mild Alzheimer's disease and assessment of diagnostic performance of z score images. AJNR Am. J. Neuroradiol 2005, 26:333-340.
36. Jacobs D., Sano M., Marder K., Bell K., Bylsma F., Lafleche G., Albert M., Brandt J., Stern Y. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology 1994, 44:1215-1220.
37. Juottonen K., Lehtovirta M., Helisalmi S., Riekkinen P.J., Soininen H. Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele. J. Neurol. Neurosurg. Psychiatry 1998, 65:322-327.
38. Kidron D., Black S.E., Stanchev P., Buck B., Szalai J.P., Parker J., Szekely C., Bronskill M.J. Quantitative MR volumetry in Alzheimer's disease. Topographic markers and the effects of sex and education. Neurology 1997, 49:1504-1512.
39. Kim E.J., Cho S.S., Jeong Y., Park K.C., Kang S.J., Kang E., Kim S.E., Lee K.H., Na D.L. Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain 2005, 128:1790-1801.
40. Klunemann H.H., Fronhofer W., Wurster H., Fischer W., Ibach B., Klein H.E. Alzheimer's second patient: Johann F. and his family. Ann. Neurol 2002, 52:520-523.
41. Lehtovirta M., Laakso M.P., Soininen H., Helisalmi S., Mannermaa A., Helkala E.L., Partanen K., Ryynanen M., Vainio P., Hartikainen P. Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience 1995, 67:65-72.
42. Mahley R.W., Weisgraber K.H., Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5644-5651. E4.
43. Maurer K., Volk S., Gerbaldo H. Auguste D and Alzheimer's disease. Lancet 1997, 349:1546-1549.
44. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
45. McLaren D.G., Kosmatka K.J., Kastman E.K., Bendlin B.B., Johnson S.C. Rhesus macaque brain morphometry: a methodological comparison of voxel-wise approaches. Methods 2009, 50:157-165.
46. Mielke R., Herholz K., Grond M., Kessler J., Heiss W.D. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol. Aging 1992, 13:93-98.
47. Mizuno Y., Ikeda K., Tsuchiya K., Ishihara R., Shibayama H. Two distinct subgroups of senile dementia of Alzheimer type: quantitative study of neurofibrillary tangles. Neuropathology 2003, 23:282-289.
48. Persson J., Lind J., Larsson A., Ingvar M., Cruts M., Van Broeckhoven C., Adolfsson R., Nilsson L.G., Nyberg L. Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD?. Neurology 2006, 66:1029-1033.
49. Pievani M., Rasser P.E., Galluzzi S., Benussi L., Ghidoni R., Sabattoli F., Bonetti M., Binetti G., Thompson P.M., Frisoni G.B. Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer's disease in vivo. Neuroimage 2009, 45:1090-1098.
50. Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol. Aging 2005, 26:355-361.
51. Raber J., Huang Y., Ashford J.W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 2004, 25:641-650.
52. Rabinovici G.D., Furst A.J., Alkalay A., Racine C.A., O'Neil J.P., Janabi M., Baker S.L., Agarwal N., Bonasera S.J., Mormino E.C., Weiner M.W., Gorno-Tempini M.L., Rosen H.J., Miller B.L., Jagust W.J. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain 2010, 133:512-528.
53. Rogaeva E. The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease. Neuromol. Med 2002, 2:1-10.
54. Roher A.E., Weiss N., Kokjohn T.A., Kuo Y.M., Kalback W., Anthony J., Watson D., Luehrs D.C., Sue L., Walker D., Emmerling M., Goux W., Beach T. Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 2002, 41:11080-11090.
55. Rose S.E., Chen F., Chalk J.B., Zelaya F.O., Strugnell W.E., Benson M., Semple J., Doddrell D.M. Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J. Neurol. Neurosurg. Psychiatry 2000, 69:528-530.
56. Sakamoto S., Ishii K., Sasaki M., Hosaka K., Mori T., Matsui M., Hirono N., Mori E. Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. J. Neurol. Sci 2002, 200:27-32.
57. Sjobeck M., Englund E. Glial levels determine severity of white matter disease in Alzheimer's disease: a neuropathological study of glial changes. Neuropathol. Appl. Neurobiol 2003, 29:159-169.
58. Sjobeck M., Haglund M., Englund E. Decreasing myelin density reflected increasing white matter pathology in Alzheimer's disease - a neuropathological study. Int. J. Geriatr. Psychiatry 2005, 20:919-926.
59. Stahl R., Dietrich O., Teipel S.J., Hampel H., Reiser M.F., Schoenberg S.O. White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology 2007, 243:483-492.
60. Stoub T.R., deToledo-Morrell L., Stebbins G.T., Leurgans S., Bennett D.A., Shah R.C. Hippocampal disconnection contributes to memory dysfunction in individuals at risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A 2006, 103:10041-10045.
61. Teipel S.J., Bayer W., Alexander G.E., Zebuhr Y., Teichberg D., Kulic L., Schapiro M.B., Moller H.J., Rapoport S.I., Hampel H. Progression of corpus callosum atrophy in Alzheimer disease. Arch. Neurol 2002, 59:243-248.
62. Teipel S.J., Stahl R., Dietrich O., Schoenberg S.O., Perneczky R., Bokde A.L., Reiser M.F., Moller H.J., Hampel H. Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neuroimage 2007, 34:985-995.
63. Wahlund L.O., Barkhof F., Fazekas F., Bronge L., Augustin M., Sjogren M., Wallin A., Ader H., Leys D., Pantoni L., Pasquier F., Erkinjuntti T., Scheltens P. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001, 32:1318-1322.
64. Yasuno F., Imamura T., Hirono N., Ishii K., Sasaki M., Ikejiri Y., Hashimoto M., Shimomura T., Yamashita H., Mori E. Age at onset and regional cerebral glucose metabolism in Alzheimer's disease. Dement. Geriatr. Cogn. Disord 1998, 9:63-67.